Sidhu, SS;Nawroth, R;Retz, M;Lemjabbar-Alaoui, H;Dasari, V;Basbaum, C
EMMPRIN regulates the canonical Wnt/beta-catenin signaling pathway, a potential role in accelerating lung tumorigenesis.
Oncogene
2010
29
29
4145-56

Tal, R;Heck, M;Teloken, P;Siegrist, T;Nelson, CJ;Mulhall, JP
Peyronie's disease following radical prostatectomy: incidence and predictors.
J Sex Med
2010
7
3
1254-61

Thalgott, M;Gschwend, JE;Retz, M
[Managing side effects of androgene deprivation in prostate cancer].
MMW Fortschr Med
2010
152
41
40-3

Rotzer, S;Fazel, J;Seidl, C;Frank, A;Autenrieth, M;Morgenstern, A;Bruchertseifer, F;Schwaiger, M;Senekowitsch-Schmidtke, R
Fractionated locoregional alpha-radioimmunotherapy of bladder cancer in a nude mouse model
Eur J Nucl Med Mol Imaging
2010
37
S281-S281

Nawroth, R;Kurzrock, A;Stöhr, R;Wild, M;Pfost, B;Sidhu, S;Hartmann, A;Retz, M
EMMPRIN (CD147): a potential new prognostic marker for tumor progression in bladder cancer
Onkologie
2010
33
151-151

Gschwendt, J;Ziller, M;Kalder, M;Lux, C;Maurer, T;Muth, M;Schmidt, K;Hadji, P
The Zotect study: Effect of zoledronic acid (Zometa (R)) on Bone Metabolism in Patients with Nreast or Prostate cancer with Bone metastases.
Onkologie
2010
33
204-204

Gschwend, JE;Retz, M;Kuebler, H;Autenrieth, M
Indications and Oncologic Outcome of Radical Cystectomy for Urothelial Bladder Cancer
Eur Urol Suppl
2010
9
1
10-18

Autenrieth, M;Kubler, H;Gschwend, JE
Adjuvant postoperative therapy for renal cell carcinoma
Onkologe
2010
16
2
150-+

Roedel, C;Weiss, C;Retz, M;Gschwend, J;Albers, P;Wullich, B;Hartmann, A;Fietkau, R;Sauer, R
Prospective randomized, multi-center phase 3 study: pre-operative chemoradiotherapy followed by cystectomy vs cystectomy in localized agvanced vesical cancer: AUO/ARO-08 Study
Strahlenther Onkol
2010
186 Suppl.
47-47

Herkommer, K;Ehrl, D;Gschwend, J;Kron, M
Prostate-Specific Antigen in Patients with Positive Family History for Prostate Cancer - blessing or curse
Onkologie
2010
33
95-95